Shattuck Labs to Join Piper Sandler Virtual Novel Targets in Immunology Symposium

Reuters
02/06
<a href="https://laohu8.com/S/STTK">Shattuck Labs</a> to Join Piper Sandler Virtual Novel Targets in Immunology Symposium

Shattuck Labs Inc., a clinical-stage biotechnology company specializing in novel therapeutics for inflammatory and immune-mediated diseases, will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, at 2:00 PM ET. The company's CEO Taylor Schreiber, M.D., Ph.D., CFO Andrew R. Neill, and Vice President of Clinical Development Michael Choi, M.D., will represent Shattuck Labs during the event. A replay of the prerecorded presentation will be available on the Events and Presentations section of Shattuck Labs' website starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date. A webcast link is provided: HERE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650089-en) on February 06, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10